Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Stopped early discontinuation based on strategic sponsor decision not driven by any safety concern

Conditions

• Atrial Fibrillation

Interventions

• DRUG: Idrabiotaparinux sodium
• DRUG: Warfarin
• DRUG: Placebo (for idrabiotaparinux)
• DRUG: Placebo (for warfarin)
• DRUG: Avidin
• DRUG: Placebo (for avidin)

Sponsor

Sanofi